Compare PKOH & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKOH | RGNX |
|---|---|---|
| Founded | 1907 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.0M | 528.6M |
| IPO Year | 1994 | 2015 |
| Metric | PKOH | RGNX |
|---|---|---|
| Price | $37.66 | $9.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $37.00 | $28.75 |
| AVG Volume (30 Days) | 89.8K | ★ 2.9M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $1,599,100,000.00 | $10,393,000.00 |
| Revenue This Year | $7.87 | $51.21 |
| Revenue Next Year | $3.42 | $19.08 |
| P/E Ratio | $67.54 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $15.52 | $5.46 |
| 52 Week High | $39.33 | $16.19 |
| Indicator | PKOH | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 61.59 | 42.39 |
| Support Level | $33.76 | $7.84 |
| Resistance Level | $39.33 | $10.56 |
| Average True Range (ATR) | 1.84 | 1.26 |
| MACD | -0.08 | -0.48 |
| Stochastic Oscillator | 79.57 | 19.37 |
Park-Ohio Holdings Corp is a diversified international company offering its clients supply chain management outsourcing services, capital equipment used on their production lines, and manufactured components used to assemble their products. The company operates through three reportable segments: Supply Technologies, Assembly Components, and Engineered Products. Maximum revenue is generated from the Supply Technologies segment, which is mainly engaged in sourcing, planning, and procurement of several production components, including fasteners, pins, nuts, bolts, valves, hoses, wire harnesses, clamps and fittings, etc. Geographically, the company generates maximum revenue from its business in the United States, followed by Europe, Asia, Mexico, Canada, and other regions.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.